LCTX 8-K: Acquisition

Filed with the SEC on Nov 12, 2026 · accession 0001193125-26-458377

LCTX filed a 8-K (current report) with the SEC on Nov 12, 2026. Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, gaining the clinical-stage HUNT1 program for Huntington's Disease. The stock moved -10.8% by the first close after the filing.

Summary of the filing

Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, gaining the clinical-stage HUNT1 program for Huntington's Disease. The deal includes $2.4 million cash, 2.2 million shares, and up to $53.4 million in future milestone payments.

For details, click here →How to read a 8-K →

Key details

Cash paid to Sellers at closing$2.4M

Value of Lineage common shares issued to Sellers$2.1M

Expense fund for Sellers' representative$200K

Payment to satisfy NeuroAirmid's third-party obligations$1.7M

Payment due on first anniversary of closing$5.4M

Contingent milestone payments for HUNT1 program$48.0M

CIRM translational funding for HUNT1 program$16.0M

CIRM award for REGEN4HD clinical study$12.0M

Lineage co-funding obligation for CIRM grant$3.1M

Acquired company, now wholly owned subsidiaryNeuroAirmid Therapeutics, Inc.

Licensor of hunt1 programThe Regents of the University of California

Grant funding providerCalifornia Institute for Regenerative Medicine (CIRM)

Representative of the sellersLeslie Thompson

How LCTX stock reacted

Close before

$1.11

Nov 11, 2026

First close after

-10.78%

$0.99

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for LCTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for LCTX?

Click here

Frequently asked questions

What did LCTX file with the SEC on Nov 12, 2026?

LCTX filed a 8-K (Acquisition). Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, gaining the clinical-stage HUNT1 program for Huntington's Disease. The deal includes $2.4 million cash, 2.2 million shares, and up to $53.4 million in future milestone payments.

What does a acquisition mean for LCTX stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did LCTX stock react to this filing?

LCTX closed at $1.11 before the filing and $0.99 on Nov 12, 2026 (-10.78%).

Other LCTX SEC filings

Get alerts when LCTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

LCTX overview LCTX analysis LCTX news Latest SEC filings